Investigation of diclofenac release and dynamic structural behavior of non-lamellar liquid crystal formulations during in situ formation by UV-Vis imaging and SAXS

Assessment of subcutaneously administered insulins using in vitro release cartridge: Medium composition and albumin binding

Biotherapeutics is the fastest growing class of drugs administered by subcutaneous injection. In vitro release testing mimicking physiological conditions at the injection site may guide formulation development and improve biopredictive capabilities. Here, anin vitrorelease cartridge (IVR cartridge) comprising a porous agarose matrix emulating subcutaneous tissue was explored. The objective was to assess effects of medium composition and incorporation of human serum albumin into the matrix. Drug disappearance was assessed for solution, suspension and in situ precipitating insulin products (Actrapid, Levemir, Tresiba, Mixtard 30, Insulatard, Lantus) using the flow-based cartridge. UV-Vis imaging and light microscopy visualized dissolution, precipitation and albumin binding phenomena at the injection site. Divalent cations present in the release medium resulted in slower insulin disappearance for suspension-based and in situ precipitating insulins. Albumin-binding acylated insulin analogs exhibited rapid disappearance from the cartridge; however, sustained retention was achieved by coupling albumin to the matrix. An in vitro-in vivorelation was established for the non-albumin-binding insulins.The IVR cartridge is flexible with potential in formulation development as shown by the ability to accommodate solutions, suspensions, and in situ forming formulations while tailoring of the system to probe in vivo relevant medium effects and tissue constituent interactions.

Small-angle X-ray and neutron scattering applied to lipid-based nanoparticles: Recent advancements across different length scales

Lipid-based nanoparticles (LNPs), ranging from nanovesicles to non-lamellar assemblies, have gained significant attention in recent years, as versatile carriers for delivering drugs, vaccines, and nutrients. Small-angle scattering methods, employing X-rays (SAXS) or neutrons (SANS), represent unique tools to unveil structure, dynamics, and interactions of such particles on different length scales, spanning from the nano to the molecular scale. This review explores the state-of-the-art on scattering methods applied to unveil the structure of lipid-based nanoparticles and their interactions with drugs and bioactive molecules, to inform their rational design and formulation for medical applications. We will focus on complementary information accessible with X-rays or neutrons, ranging from insights on the structure and colloidal processes at a nanoscale level (SAXS) to details on the lipid organization and molecular interactions of LNPs (SANS). In addition, we will review new opportunities offered by Time-resolved (TR)-SAXS and -SANS for the investigation of dynamic processes involving LNPs. These span from real-time monitoring of LNPs structural evolution in response to endogenous or external stimuli (TR-SANS), to the investigation of the kinetics of lipid diffusion and exchange upon interaction with biomolecules (TR-SANS). Finally, we will spotlight novel combinations of SAXS and SANS with complementary on-line techniques, recently enabled at Large Scale Facilities for X-rays and neutrons. This emerging technology enables synchronized multi-method investigation, offering exciting opportunities for the simultaneous characterization of the structure and chemical or mechanical properties of LNPs.

Recent Advances in Antibacterial Coatings to Combat Orthopedic Implant-Associated Infections

Implant-associated infections (IAIs) represent a major health burden due to the complex structural features of biofilms and their inherent tolerance to antimicrobial agents and the immune system. Thus, the viable options to eradicate biofilms embedded on medical implants are surgical operations and long-term and repeated antibiotic courses. Recent years have witnessed a growing interest in the development of robust and reliable strategies for prevention and treatment of IAIs. In particular, it seems promising to develop materials with anti-biofouling and antibacterial properties for combating IAIs on implants. In this contribution, we exclusively focus on recent advances in the development of modified and functionalized implant surfaces for inhibiting bacterial attachment and eventually biofilm formation on orthopedic implants. Further, we highlight recent progress in the development of antibacterial coatings (including self-assembled nanocoatings) for preventing biofilm formation on orthopedic implants. Among the recently introduced approaches for development of efficient and durable antibacterial coatings, we focus on the use of safe and biocompatible materials with excellent antibacterial activities for local delivery of combinatorial antimicrobial agents for preventing and treating IAIs and overcoming antimicrobial resistance.

Biotransformation of diclofenac by isolated super-degrader Pseudomonas sp. DCα4: Postulated pathways, and attenuated ecotoxicological effects

Significant concentrations of emerging xenobiotics, like diclofenac (DCF), possessing severe irreversible eco-toxicological threats, has been detected in aquatic systems worldwide, raising the concerns. This present investigation is intended to explore an efficient solution to support the existing wastewater treatment policies to handle DCF contamination by bacteria-mediated biotransformation. DCF-tolerant bacterial strains were isolated from pharmaceutical wastewater and selected based on their non-virulence nature and degradation ability. Among those, Pseudomonas sp. DCα4 was found to be the most dominant DCF degrader exhibiting 99.82% removal of DCF confirmed by HPLC after optimization of temperature at 30.02 °C, pH at 6.9, inoculum of 4.94%, and time 68.02 h. The degradation kinetics exhibited the process of DCF degradation followed a first-order kinetics with k of 0.108/h and specific degradation rate of 0.013/h. Moreover, the enzyme activity study indicated predominant hydrolase activity in the DCF treatment broth of DCα4, implying hydrolysis as the main force behind DCF biotransformation. HRMS analysis confirmed the presence of 2-hydroxyphenylacetic acid, 1,3-dichloro,2-amino, 5-hydroxybenzene, and benzylacetic acid as major intermediates of DCF biodegradation indicating non-specific hydrolysis of DCF. Whole genome analysis of most related strains which were confirmed by near full 16S rRNA gene sequence homology study, predicted involvement of different N-C bond hydrolase producing genes like puud, atzF, astB, nit1, and nylB. The ecotoxicological study using Aliivibrio fischeri exhibited 47.51% bioluminescence inhibition by DCF-containing broth which was comparable to the same caused by 1 mg/mL of K2Cr2O7 whereas remediated broth exhibited only 0.51% inhibition implying reduction of the ecotoxic load caused by DCF contamination. Cost analysis revealed that possible integration of the process with existing ones would increase per litre expense by $0.45. These results indicated that the described process of DCF biodegradation using the super-degrader DCα4 would be an advancement of existing pharmaceutical wastewater treatment processes for DCF bioremediation.